Leukemia Clinical Trials

Showing 961-980 of 5,235 trials

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

NCT01951482

This is a multi-center phase 3 randomized controlled study to assess the efficacy of Pemetrexed/platinum with or without Bevacizumab on patients with brain metastasis from non-small cell lung cancer(NSCLC) harboring EGFR/ALK wild type by intracranial PFS(iPFS), also PFS ,ORR, DCR and OS. The safety is evaluated as well.

Non Squamous Non-small Cell Lung CancerBrain MetastasesBevacizumab

Sun Yat-sen University160 participantsStarted Jan 2016

Guangzhou, Guangdong, China

RECRUITINGPHASE1

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

NCT02998567

HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours. The investigators will be investigating the safety and toxicity of the combination.

Non Small Cell Lung Cancer

Royal Marsden NHS Foundation Trust60 participantsStarted Jan 2017

Sutton, Surrey, United Kingdom • London, United Kingdom

COMPLETEDNA

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

NCT03948724

The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI

Therapeutic Patient EducationImmune Checkpoint InhibitorsMelanoma+4 more

Institut Cancerologie de l'Ouest411 participantsStarted Dec 2019

Angers, France • Angers, France • Caen, France +6 more locations

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Related Searches

Fall Risk Identification and Management for Older Veterans

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

GLP-1R Agonist Treatment for Opioid Use Disorder

Validation Of A Parent Administered Symptom Score For Unsettled Infants (Every Baby is UnIQue)

Expanded Access of Sotorasib

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia